Objective To validate a symptom-based fistula screening questionnaire and estimate obstetric fistula (OF) prevalence in rural Nepal.
Introduction
Obstetric fistula (OF) is an often neglected maternal morbidity, and generally occurs in lower resource settings among women with prolonged or obstructed labour without access to timely, quality obstetric care. 1 In addition to fetal demise, the prolonged pressure of the fetus's head can restrict blood flow, causing ischaemia, necrosis, and the formation of an opening (fistula) between the woman's vagina and bladder/lower urinary tract (vesicovaginal fistula, VVF), and/or vagina and rectum (rectovaginal fistula, RVF). 2 Women with OF have constant leakage of urine and/or feces. They may also develop genital sores and dermatitis, sexual dysfunction, amenorrhoea, and lower extremity neurological deficits, such as weakness and foot drop. 3, 4 Furthermore, these women are often socially stigmatised and sustain psychological trauma. 5 Obstetric fistula (OF) is widely cited to affect between 2 and 3.5 million women globally, with 50 000-100 000 annual incident cases; however, these figures were derived from expert opinion or extrapolation of expert experience from hospital-based settings. [6] [7] [8] [9] [10] [11] [12] [13] Hospital-based studies likely underestimate prevalence as women with OF often lack access to skilled care. 7 In addition, social stigma and isolation further impedes care-seeking. A 2007 systematic review identified 29 studies with population-based incidence and prevalence estimates, and found incidence estimates ranging from 20 000 to 30 000 annual cases, with a global prevalence estimate of 654 000 cases; however, only four of these studies described their methodology for calculating these estimates. 7 Demographic and Health Surveys (DHS) in Malawi, the Democratic Republic of Congo, Ethiopia, Niger, Nigeria, Pakistan, Rwanda, and Uganda have included different symptom-based fistula questions to estimate population prevalence; however, as these questions have not been validated, the accuracy of these prevalence estimates is unknown. [14] [15] [16] [17] [18] [19] [20] A 2013 systematic review and meta-analysis found only ten studies that used clinically confirmed cases to estimate community-based OF prevalence; 21 four of these were conducted in sub-Saharan Africa or South Asia. [22] [23] [24] [25] Subsequent to the review, two population-based cross-sectional studies from southern Sudan and Pakistan used confirmatory clinical examinations; however, neither of these studies used a control population to assess the validity of the screening questions used to identify cases. 26, 27 At present, there is no widely used, well-validated fistula screening tool. This study aimed to determine the validity of a symptom-based, fistula screening questionnaire, and estimate obstetric fistula prevalence in a community-based rural setting in Nepal. A community-based cross-sectional survey (screening phase) was followed by a nested casecontrol study with a clinical examination of potential cases and non-cases (validation phase).
Methods

Study design and site
A community-based cross-sectional survey of parous, reproductive age women was conducted in 136 communities (sectors) of Sarlahi District in rural southern Nepal, which encompassed a population of approximately 80 000, to identify all households with women of childbearing age. The study was nested in a randomised controlled trial on the impact of sunflower oil massage on neonatal morbidity (L. Mullany, principal investigator; trial registered at clinicaltrials.gov, NCT01177111). Nepal is a low income country with a gross national income per capita of $600 in 2011. Sarlahi District is comprised of mostly rural agrarian communities, with 75% of the population living below the Nepali poverty line, <20% of home births attended by skilled attendants, and <10% of births occurring in a health care facility (2010). 32 A screening questionnaire was designed to assess current experience of VVF and RVF symptoms, as well as stress and urge urinary incontinence (SUI and UUI, respectively), fecal incontinence (FI), and pelvic organ prolapse (POP). Women who screened positive on the questionnaire were selected for inclusion in a nested case-control study. Two types of controls were randomly selected among women who screened negative, in a ratio of 1 : 4 : 4 (case : control : control). The first type included women with reported symptoms of UI and/or FI. The second type were women who did not have incontinence or fistula symptoms. All consenting cases and controls underwent a confirmatory clinical examination by one female urogynaecologist/female pelvic medicine and reconstructive surgeon, blinded to the screening results. In addition to fellowship training and board certification by the American Board of Obstetrics and Gynecology in Female Pelvic Medicine and Reconstructive Surgery, this urogynaecologist also underwent specific training in diagnosing and caring for obstetric fistula patients in Ethiopia and Nepal.
To complement this survey-based approach to identifying potential cases of OF, we carried out a case-finding strategy using local research interviewers who lived within our study population to identify women suspected of having OF but who were not included in the cross-sectional screening survey. We also encouraged women who presented for clinical examination to let us know of any women in their community with OF symptoms. Surgical care for any identified cases of OF or other gynaecological pathology were offered without charge. Institutional review board approval was obtained from both Johns Hopkins School of Public Health (Baltimore, MD, USA) and the Institute of Medicine, Tribhuvan University (Kathmandu, Nepal).
Fistula screening tool
The OF screening questionnaire included VVF and RVF symptom questions that were originally developed by the late Thomas Elkins (Professor, Johns Hopkins Department of Gynecology and Obstetrics), and UI, FI, and POP screening questions previously validated in the USA and other countries. [33] [34] [35] [36] Further face validity with modification of the questionnaire as appropriate was performed after consultation with expert fistula surgeons in the USA, Ethiopia, UK, and Nepal. The resultant OF screening questionnaire was further refined after discussion among all levels of study personnel, and translated into both Nepali and Maithili. These versions were back-translated and pilot-tested among the Maithili-speaking field interviewers.
Vesicovaginal fistula (VVF) was defined as a positive response to either of the following two questions: (1) 'Currently, does your clothing get wet with your urine during sleep?'; (2) 'When you are not urinating, do you currently experience continuously dripping urine through the birth canal that you cannot stop?'. If the women answered yes to either question, they were subsequently asked if the urine leakage occurred 'all day and all night'. Similarly, RVF was defined as a positive response to the following question: 'When you are not defecating, do you currently experience feces passing through the birth canal that you cannot stop?'.
In addition, women were asked for the month and year of their last delivery and of the onset of OF symptoms. The two dates were compared in order to determine whether the onset of symptoms corresponded with the delivery. Finally, both the VVF and RVF screening questionnaires included a subjective observation by the interviewer of the wetness of the subject's clothes from urine/feces, or for the smell of urine/feces around the subject.
All women who screened positive for OF were approached to be included in the nested case-control study and to undergo clinical examinations. Women who screened negative for OF were entered into a pool and randomly selected for the nested case-control study. Specifically, two types of controls were selected: those who reported incontinence symptoms (incontinence controls) and those who had no incontinence symptoms (true controls) in a ratio of 1 : 4 : 4 (case : incontinence control : true control). Pelvic examinations were performed following standard care to confirm the presence or absence of pelvic fistula. Specifically, any participant found to have watery fluid in the vagina without a clear VVF also underwent additional examination procedures, including a dye test (presence of blue or orange staining on a gauze pad placed in the vagina after retrograde filling of the bladder with blue-dyed sterile saline, and/or excretion of orange urine from the kidneys after study participants ingest phenazopyridine) to confirm the presence of a bladder and/or ureteral fistula. Any participant found to have stool and/or foul-smelling discharge in the vagina without a clear RVF underwent additional examination procedures, including a dye test (presence of blue staining on a gauze pad placed in the vagina after inserting blue-dyed water-soluble lubricating jelly in the rectum), and/or a flat tire test (presence of air bubbles in the vagina after pumping the rectum with air while maintaining fluid in the vagina), to confirm the presence of rectal fistula. We also performed the above test (s) on participants who reported symptoms suspicious for VVF and/or RVF on the day of clinical examination if no clear fistula tract was found. Finally, at the end of each examination session, we performed the aforementioned tests on any participants who screened positive for OF symptoms but who were not found to have a clear fistula tract on initial examination. As an additional safeguard against missing any fistula cases, our research protocol also included performing radiologic tests, such as intravenous pyelogram and/or barium enema studies on participants who reported suspicious symptoms but who were still not found to have a fistula after the aforementioned examination procedures.
Analysis
The overall frequencies of women's self-reported OF symptoms were compared with clinical examination diagnosis, and the sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) of the tool were calculated. Population prevalence and 95% confidence intervals were calculated using the Wilson score interval. 28, 29 Descriptive analyses consisted of frequencies for categorical variables and means and standard deviations for continuous data. Bivariate analyses of characteristics of VVF false positives and true negatives were conducted, and a multivariate model was used to assess which characteristics were most strongly associated with false-positive status. Additionally, a comparison of VVF screening questions was conducted by false-positive or true-negative status, as well as by case-control status, to identify which questions, or combination of questions, most accurately classified women. Chi-square tests were performed for categorical values and Student's t-tests were performed for continuous variables. The data were analysed in SAS 9.3 (Cary, NC, USA), and all statistical tests were double-sided at the 5% level. 30 
Results
There were 18 383 parous women of reproductive age identified from the sunflower oil trial database (Figure 1 ). Among these, 17 051 (93%) met the eligibility criteria and 16 893 (97%) completed the cross-sectional screening. Only four women (0.02%) refused the questionnaire, and 154 could not be found at home or had moved (0.9%). None of the women who consented to the questionnaire refused to answer any questions, and the percentage of women who responded 'Don't know' for any given question was low (<0.1%). It took 30 minutes or less to complete the screening questionnaire.
Women's self-reported OF status in the VVF/RVF screen resulted in 68 screened-positive cases: VVF-only symptoms (66, 0.4%), RVF-only symptoms (1, 0.01%), and both RVF and VVF symptoms (1, 0.01%). All 68 screened-positive cases were recruited for the case-control study. There were 16 825 women who screened negative for OF: 4590 (27%) with incontinence symptoms and 12 222 (73%) without incontinence symptoms. In accordance with the 1 : 4 : 4 (case : control : control) ratio, a total of 538 controls (269 incontinence controls and 269 non-incontinent/true controls) were randomly selected for the case-control study from women who had screened negative.
Among the screened-positive cases (68), 13 women declined to participate or were not found: 12 with VVF- 
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ª 2016 Royal College of Obstetricians and Gynaecologists only symptoms and one with RVF-only symptoms. Of the 55 women who underwent clinical examination (81%), one case of VVF and one case of concomittant VVF and RVF were confirmed. Both of these cases occurred in women following obstructed labour, for which they received caesarean sections, and were not associated with other potential causes of pelvic fistula such as sexual assault or other pelvic injury. The remaining 53 women were false positives and were reclassified as 41 incontinence controls and 12 true controls after clinical examination and detailed interview. Among the 538 screened-negative controls selected to be in the case-control study, 353 (66%) completed the clinical examination. There were no false negatives. After reclassifying the 53 false positives as controls, there were 203 clinically confirmed incontinence controls and 203 continent/ true controls. The screening tool correctly identified both OF cases. No cases of VVF or RVF were found after examining the control patients (no false negatives). Using our case-finding strategy, we identified two additional OF cases (both VVF only). Both of these women were not included in our cross-sectional study as they were not screened and therefore ineligible for the nested case-control study.
VVF/RVF screening validation
The VVF screening tool had a sensitivity of 100% (95% CI 34.2-100.0%) and specificity of 86.9% (95% CI 83.3-89.9%), with a positive predictive value of 3.6% (95% CI 1.0-12.3%) and a negative predictive value of 100% (95% CI 98.9-100.0%). The RVF screening tool had a sensitivity of 100% (95% CI 20.7-100.0%) and specificity of 99.8% (95% CI 98.6-100%), with a positive predictive value of 50% (95% CI 9.5-90.5%) and a negative predictive value of 100% (95% CI 99.1-100.0%).
The prevalence of VVF was 11.8 per 100 000 reproductive age, parous women (95% CI 3.2-43.2). The prevalence of RVF was 5.9 per 100 000 reproductive age, parous women (95% CI 1.0-33.5). The prevalence for either type of obstetric fistula is estimated to be 12 per 100 000 women (95% CI 3-43).
Characteristics associated with false-positive classification of VVF
In order to improve the OF screening tool and reduce the false-positive rate, an analysis of clinically confirmed VVF false positives (n = 53) was conducted. There were no RVF false positives. Among VVF false positives, 77% had some type of urinary incontinence: six SUI only (11%), four UUI only (8%), and 31 SUI and UUI (59%). Additionally, 11 (23%) had POP and 26 (49%) had vaginal discharge present at the time of examination. Only three women (6%) were without urinary incontinence, POP, or vaginal discharge.
Compared with true negatives, VVF false positives were older (35 versus 32 years, P = 0.03), had higher gravidity (4.6 versus 3.7, P = 0.001), and had more vaginal deliveries (4.3 versus 3.5, P < 0.001) ( Table 1) . Additionally, VVF false positives were less likely to have stress incontinence only (11% versus 24%, P = 0.02), but were more likely to have both SUI and UUI (59% versus 15%, P < 0.001); however, only having both SUI and UUI remained significantly associated with false-positive status in a multivariate model (Table 1b) . Compared with true negatives, the odds of having both SUI and UUI was more than eight times higher among false positives (odds ratio, OR 8.23, 95% CI 3.79-17.84, P < 0.001).
Comparison of VVF screening questions
Analyses of responses to each VVF screening question by false-positive/true-negative status (Table 2 ) and by casecontrol group (OF cases, incontinence controls, true controls; Table 3 ) suggested the high specificity of all questions in correctly classifying women (all P < 0.001). The clinically confirmed VVF cases responded positively to all of the VVF screening questions, and the interviewers reported being able to see that the clothing of these women were wet with urine. Only one of the two cases was observed to have a smell of urine around her.
True negatives did not respond 'Yes' to any of the VVF screening questions, nor were they observed to have an odor or wetness from urine ( Table 2) . Of the two VVF case-defining questions, nearly all the false positives responded 'Yes' to VVF question 2, 'Currently does your clothing get wet with your urine during sleep?' (48, 91%), whereas fewer responded 'Yes' to VVF question 3, 'When you are not urinating, do you currently experience continuously dripping urine through the birth canal that you cannot stop?' (35, 66%). The false-positive rate decreased to 43% (23) when women were additionally asked whether this dripping of urine occurred all day and all night (VVF question 3a). The VVF screening question that had the lowest false-positive response rate and which did not misclassify any fistula cases, was the interviewer observation VVF question 7, 'Do you think you see wetness around the subject from her own urine?' (8, 15%). Combinations of the VVF screening questions were assessed to determine the smallest number of questions that would result in the lowest number of false-positive responses while not misclassifying any true cases. The most discriminating combinations of questions included the interviewer observation of wetness around the women, VVF questions 3 and 3a, 'Do you currently experience continuously dripping urine through the birth canal that you cannot stop all day and all night?' and VVF questions 1 and 4, which assessed whether the VVF symptoms occurred after the woman's last delivery. This combination resulted in only five false positives (9%). Incontinence controls were more likely to respond positively to each of the VVF screening questions compared with true controls (14-20% versus 4-6%, P < 0.001; Table 3 ). Although the observational questions distinguished the fistula cases from any controls, they were less useful for discriminating between incontinence controls and true controls.
Discussion
Main findings
In this population-based study of reproductive-age, parous women in the Sarlahi District of rural Nepal (n = 16 893 women), our OF screening questionnaire demonstrated high sensitivity and specificity for VVF and RVF, and estimated low VVF and RVF prevalence (12/100 000). Although women with OF may be socially isolated and do not present for screening or care, it is notable that our case-finding strategy, which used word-of-mouth referral from local female research interviewers and women who presented for clinical examinations, resulted in only two additional cases of OF in women that were from the Sarlahi District but not within our surveyed sectors.
Strengths and limitations
The community-based design with case-finding strategy increased our confidence in the accuracy of our OF prevalence estimate. Hospital-based designs are likely to underestimate OF prevalence, as women with OF often lack access to health facilities and experience social stigmatisation. A 2013 systematic review and meta-analysis of OF prevalence studies found that hospital-based OF prevalence estimates (51 per 100 000 reproductive-age women in hospital-based studies in sub-Saharan Africa) were lower than communitybased estimates (160 per 100 000 reproductive-age women in sub-Saharan Africa; 120 per 100 000 in South Asia). 21 Although the screening questionnaire performed adequately in a low OF prevalence setting, our statistics were driven by the large number of women without OF symptoms (large number of true negatives, no false negatives). Furthermore, the screening questionnaire had a low positive predictive value (two true positives out of 55 screened positives). In other similarly low prevalence settings, performing confirmatory clinical examinations on a *Delivery dates and dates of VVF symptom initiation were compared, and women whose reported VVF symptoms occurred after delivery were counted as a positive response.
small number of screened-positive women (in this case, 55 out of 16 893 women) would be feasible, but this may not be feasible when OF prevalence is higher. Before the questionnaire can be used, it must undergo further validation in a population with a higher suspected OF prevalence. We demonstrated that the OF screening questionnaire was feasible to administer by female field interviewers with a high-school education and was understood by mostly illiterate women. Significantly, this screening questionnaire did not miss any VVF or RVF cases (there were no false negatives). The analysis of the OF screening tool questions demonstrated that a combination of symptom-based and observational questions may yield the most accurate VVF prevalence estimates with the lowest false-positive rate.
Notably, the observational questions (observation of wetness, including wet clothing) generated the smallest number of false-positive cases while correctly classifying 100% of fistula cases. These observational questions may be particularly applicable in low-literacy settings; however, using them in isolation should be cautioned as it may lead to OF cases being missed, as urine production varies throughout the day and incontinence barriers may mask urine wetness.
Interpretation
Although most published estimates of OF prevalence, including the recent 2013 meta-analysis, 21 found much higher OF prevalence than our study, most reports did not include clinical confirmation of cases or were too small to accurately estimate prevalence. This is a potentially consequential limitation of these studies in light of our finding of 53 false-positive VVF cases in this low-prevalence setting. Additionally, compared with true negatives, false positives were eight times more likely to have both SUI and UUI symptoms, after controlling for age, parity, and symptoms of only SUI or UUI. Therefore, studies of OF prevalence without a confirmatory examination may result in over-estimation by the inclusion of women with incontinence. This may be an even more significant issue as by most approximations the prevalence of urinary incontinence in most populations is much higher than the prevalence of OF.
The OF prevalence estimates from other populationbased studies with confirmatory clinical examinations from sub-Saharan Africa and South Asia vary widely, and were significantly higher than those found in our study: 162 per 100 000 women (95% CI 153-264) in Ethiopia (n = 19 153); 22 95 per 100 000 women (95% CI 2-526) in Gambia (n = 1038); 23 30 per 100 000 women (95% CI 10-100) in Southern Sudan (n = 8865); 26 86 per 100 000 (95% CI 2-480) in Maharashtra, India (n = 1167); 24 260 per 100 000 (95% CI 7-1439) in Karnataka, India; 25 and 390 per 100 000 women (95% CI 220-570) or 450 per 100 000 parous women (95% CI 250-650) in Pakistan (n = 5064). 27 Notably, these studies used different sampling methodologies and none of the studies examined controls (women who did not report symptoms of OF). Additionally, whereas our estimate (12/100 000; 95% CI 3-43) was within the 95% confidence intervals of the estimates from Gambia and India, those studies had very wide confidence intervals, probably as a result of small sample sizes; the large sample size used in our study (n = 16 893) yielded a more precise prevalence estimate. Insights from Nepali experts in the country suggest that OF may be more common in the mountainous regions of rural Nepal instead of the flat plains of the Terai region in which Sarlahi is situated. Additionally, our study population was limited to women of reproductive age, and the OF screening questions asked only about current experience of OF symptoms. Consequently, we would have missed women with a history of OF who underwent previous repair and older women with OF symptoms; however, using our additional case-finding strategy, we found only two additional cases of OF.
Although exact estimates may be unclear, it is probable that OF significantly impacts millions of women in parts of sub-Saharan Africa and South Asia. Population-based prevention and treatment strategies would significantly improve the quality of life of affected individuals and their communities. As most of the populations at risk for OF live in rural areas, sending skilled personnel to remote places to perform physical examinations requires significant resources, which is often prohibitive in resource-limited settings. This underscores the need for a validated questionnaire that can accurately diagnose women with OF and be easily administered to a large population. Without an accurate measure of OF incidence, it is not possible to know if healthcare resources are adequately or effectively allocated. There are currently no published, rigorously studied, OF screening tools. A 2013 study in Nigeria found that the DHS fistula module had a 92% sensitivity and 83% specificity among a sample of 268 women who presented to facilities based on perceived fistula-like symptoms. The authors clearly noted, however, that this could not be considered a validation study because of the sample restrictions. 31 
Conclusion
The OF screening questionnaire was feasible to administer by female field interviewers with a high-school education, and demonstrated excellent sensitivity and specificity in this population of women with low fistula prevalence. The low OF prevalence in this study suggests that higher prevalence estimates from sub-Saharan African or hospital-based studies are not generalisable to our population in rural South Asia. Findings from our analysis of the false-positive population in our study further calls into question previous population-based estimates, as these estimates may capture women with incontinence. A useful OF screening tool needs to distinguish fistula symptoms from incontinence symptoms. We found that a combination of symptombased and observational questions may yield the most accurate VVF prevalence estimates. The RVF case-defining question appeared to effectively identify RVF cases, as there were no RVF false positives; however, the low OF population prevalence in this setting prohibited any meaningful assessment of the predictive value of the tool. Follow-up studies in higher prevalence settings are needed to further validate the tool.
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